Pramipexole for the treatment of early Parkinson's disease.
Identifieur interne : 000D47 ( Ncbi/Curation ); précédent : 000D46; suivant : 000D48Pramipexole for the treatment of early Parkinson's disease.
Auteurs : Santiago Perez-Lloret [France] ; Santiago Perez Lloret ; María Ver Nica Rey ; Luca Ratti ; Olivier RascolSource :
- Expert review of neurotherapeutics [ 1744-8360 ] ; 2011.
English descriptors
- KwdEn :
- MESH :
- chemical , pharmacokinetics : Antiparkinson Agents, Benzothiazoles.
- chemical , therapeutic use : Antiparkinson Agents, Benzothiazoles.
- drug therapy : Parkinson Disease.
- Animals, Clinical Trials as Topic, Humans.
Abstract
Pramipexole is a nonergolinic dopamine agonist, with high affinity for the D2 subfamily of dopamine receptors. Pramipexole is efficacious for the symptomatic treatment of early Parkinson's Disease (PD) and its early use, before that of levodopa can delay the emergence of levodopa-related motor complication. Dosage should be increased gradually from a starting dose of 0.375 mg/day up to a maximum of 4.5 mg/day in equally divided doses taken three times per day with pramipexole immediate-release or equivalent daily dosages once-daily with pramipexole extended-release. Pramipexole can also improve depressive symptoms and possibly health-related quality of life in PD. Nonetheless, its use is not devoid of tolerability problems. While peripheral adverse drug reactions, such as nausea, vomiting or orthostatic hypotension, can be effectively treated and usually pose few problems to most patients, neuropsychiatric events can seriously limit the use of pramipexole in some cases. Indeed, excessive daytime somnolence, impulse-control disorders, hallucinations or delusions can severely affect patients, causing important personal or social handicap. Patients should be informed about the risk of such neuropsychiatric complications and their presence should be actively detected at each consultation. More effort will have to be put into further studying the risk-benefit ratio of pramipexole and other dopamine agonists in the treatment of early PD.
DOI: 10.1586/ern.11.75
PubMed: 21721909
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000962
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :000922
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000922
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000D47
Links to Exploration step
pubmed:21721909Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pramipexole for the treatment of early Parkinson's disease.</title><author><name sortKey="Perez Lloret, Santiago" sort="Perez Lloret, Santiago" uniqKey="Perez Lloret S" first="Santiago" last="Perez-Lloret">Santiago Perez-Lloret</name><affiliation wicri:level="3"><nlm:affiliation>Departments of Clinical Pharmacology and Neurosciences, University Hospital and University of Toulouse, France and INSERM CIC-9023 and UMR-825, Toulouse, France; Department of Clinical Pharmacology, Faculty of Medicine, 37 Allées Jules Guesde, 31000, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Departments of Clinical Pharmacology and Neurosciences, University Hospital and University of Toulouse, France and INSERM CIC-9023 and UMR-825, Toulouse, France; Department of Clinical Pharmacology, Faculty of Medicine, 37 Allées Jules Guesde, 31000, Toulouse</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Perez Lloret, Santiago" sort="Perez Lloret, Santiago" uniqKey="Perez Lloret S" first="Santiago" last="Perez Lloret">Santiago Perez Lloret</name></author><author><name sortKey="Rey, Maria Ver Nica" sort="Rey, Maria Ver Nica" uniqKey="Rey M" first="María Ver Nica" last="Rey">María Ver Nica Rey</name></author><author><name sortKey="Ratti, Luca" sort="Ratti, Luca" uniqKey="Ratti L" first="Luca" last="Ratti">Luca Ratti</name></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:21721909</idno><idno type="pmid">21721909</idno><idno type="doi">10.1586/ern.11.75</idno><idno type="wicri:Area/PubMed/Corpus">000962</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000962</idno><idno type="wicri:Area/PubMed/Curation">000922</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000922</idno><idno type="wicri:Area/PubMed/Checkpoint">000922</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000922</idno><idno type="wicri:Area/Ncbi/Merge">000D47</idno><idno type="wicri:Area/Ncbi/Curation">000D47</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Pramipexole for the treatment of early Parkinson's disease.</title><author><name sortKey="Perez Lloret, Santiago" sort="Perez Lloret, Santiago" uniqKey="Perez Lloret S" first="Santiago" last="Perez-Lloret">Santiago Perez-Lloret</name><affiliation wicri:level="3"><nlm:affiliation>Departments of Clinical Pharmacology and Neurosciences, University Hospital and University of Toulouse, France and INSERM CIC-9023 and UMR-825, Toulouse, France; Department of Clinical Pharmacology, Faculty of Medicine, 37 Allées Jules Guesde, 31000, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Departments of Clinical Pharmacology and Neurosciences, University Hospital and University of Toulouse, France and INSERM CIC-9023 and UMR-825, Toulouse, France; Department of Clinical Pharmacology, Faculty of Medicine, 37 Allées Jules Guesde, 31000, Toulouse</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Perez Lloret, Santiago" sort="Perez Lloret, Santiago" uniqKey="Perez Lloret S" first="Santiago" last="Perez Lloret">Santiago Perez Lloret</name></author><author><name sortKey="Rey, Maria Ver Nica" sort="Rey, Maria Ver Nica" uniqKey="Rey M" first="María Ver Nica" last="Rey">María Ver Nica Rey</name></author><author><name sortKey="Ratti, Luca" sort="Ratti, Luca" uniqKey="Ratti L" first="Luca" last="Ratti">Luca Ratti</name></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name></author></analytic><series><title level="j">Expert review of neurotherapeutics</title><idno type="eISSN">1744-8360</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiparkinson Agents (pharmacokinetics)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Benzothiazoles (pharmacokinetics)</term><term>Benzothiazoles (therapeutic use)</term><term>Clinical Trials as Topic</term><term>Humans</term><term>Parkinson Disease (drug therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antiparkinson Agents</term><term>Benzothiazoles</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Benzothiazoles</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Clinical Trials as Topic</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Pramipexole is a nonergolinic dopamine agonist, with high affinity for the D2 subfamily of dopamine receptors. Pramipexole is efficacious for the symptomatic treatment of early Parkinson's Disease (PD) and its early use, before that of levodopa can delay the emergence of levodopa-related motor complication. Dosage should be increased gradually from a starting dose of 0.375 mg/day up to a maximum of 4.5 mg/day in equally divided doses taken three times per day with pramipexole immediate-release or equivalent daily dosages once-daily with pramipexole extended-release. Pramipexole can also improve depressive symptoms and possibly health-related quality of life in PD. Nonetheless, its use is not devoid of tolerability problems. While peripheral adverse drug reactions, such as nausea, vomiting or orthostatic hypotension, can be effectively treated and usually pose few problems to most patients, neuropsychiatric events can seriously limit the use of pramipexole in some cases. Indeed, excessive daytime somnolence, impulse-control disorders, hallucinations or delusions can severely affect patients, causing important personal or social handicap. Patients should be informed about the risk of such neuropsychiatric complications and their presence should be actively detected at each consultation. More effort will have to be put into further studying the risk-benefit ratio of pramipexole and other dopamine agonists in the treatment of early PD.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D47 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 000D47 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:21721909
|texte= Pramipexole for the treatment of early Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:21721909" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |